Oesophageal cancer: RNA editing of SLC22A3 mRNAs: causative relevance to familial ESCC?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

1. Identification of loci of functional relevance to Barrett's esophagus and esophageal adenocarcinoma: Cross-referencing of expression quantitative trait loci data from disease-relevant tissues with genetic association data.PloS one · 2019
   Pooled it
2. Gastrointestinal cancer: molecular pathogenesis and targeted therapy.Molecular biomedicine · 2025
   Review
3. SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia.Clinical epigenetics · 2022
   Article
4. The role of RNA editing enzyme ADAR1 in human disease.Wiley interdisciplinary reviews. RNA · 2022
   Review

Corrections and comments

• Comment on
  RNA editing of2017

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as